title: Tumor markers in mature cystic teratomas of the ovary.
abstract: OBJECTIVE
  The objective of this study was to evaluate the serum levels of tumor markers in patients with ovarian mature cystic teratomas.
  
  
  METHODS
  Retrospective study of 215 patients operated at Zekai Tahir Burak Women Health Education and Research Hospital between January 2001 and October 2006 was performed.
  
  
  RESULTS
  The median age was 36 years (range 13-80). The mean tumor diameter was 7.7 +/- 4.6 cm (range 2-25). The mean serum CA 125 level was 26.2 +/- 29.9 U/mL (range 1.4-225, normal value <35), and the mean serum CA 19-9 level was 83.5 +/- 179.2 IU/mL (range 0.6-1,000; normal value <37). The elevated rate of CA 19-9, CA 125 was 39.6% (74/187) and 23.3% (50/215), respectively. The mean age of patients and the rate of bilaterality of tumors were similar in both patients with elevated CA19-9 and with normal CA 19-9 level (P > 0.05). The mean tumor size of patients with elevated CA 19-9 was greater than those with normal CA19-9 level (P = 0.01).
  
  
  CONCLUSIONS
  Serum CA 19-9 has the highest positivity rate among other tumor markers in ovarian mature cystic teratomas. Elevated serum CA 19-9 levels are correlated with larger tumor size. But the diagnostic value of elevated CA 19-9 in patients with MCT would be poor if the test was used alone.
authors.forename: Emin
authors.initials: E
authors.lastname: Ustunyurt
authors.affiliation: The Department of Obstetrics and Gynecology, Zekai Tahir Burak Women's Health Education Hospital, Ankara, Turkey. dreminustunyurt@yahoo.com.tr
authors.forename: Ustunyurt
authors.initials: U
authors.lastname: Emin
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
authors.forename: Gungor
authors.initials: G
authors.lastname: Tayfun
authors.forename: Cantekin
authors.initials: C
authors.lastname: Iskender
authors.forename: Iskender
authors.initials: I
authors.lastname: Cantekin
authors.forename: Basak Ozlem
authors.initials: BO
authors.lastname: Ustunyurt
authors.forename: Ustunyurt Basak
authors.initials: UB
authors.lastname: Ozlem
authors.forename: Umit
authors.initials: U
authors.lastname: Bilge
authors.forename: Bilge
authors.initials: B
authors.lastname: Umit
authors.forename: Leyla
authors.initials: L
authors.lastname: Mollamahmutoglu
authors.forename: Mollamahmutoglu
authors.initials: M
authors.lastname: Leyla
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D012189:Retrospective Studies; D013724:Teratoma / Q000097:blood* / Q000473:pathology / Q000601:surgery; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D000509:alpha-Fetoproteins